11 results about "Schisandrin B" patented technology

The present invention discloses the use of schisandra extract in a preparation for preventing and treating hair loss or promoting hair regeneration, belonging to the field of hair loss treatment. The schisandra of the present invention includes a combination of one or more of schisandra A and schisandra B. The present invention found that both schisandra A and schisandra B can significantly promote the proliferation of hair follicle cells; schisandra B can significantly promote hair regeneration after androgenic alopecia, and at the same time, the effect of promoting hair regeneration is related to the concentration of schisandra B. The present invention relates to a drug for treating hair loss, which includes schisandra A and schisandra B and a drug combination, as well as an optional pharmaceutically acceptable carrier. The drug can be prepared into different dosage forms such as external use solution, lotion, liniment, ointment, plaster, paste, patch, etc. for convenient use.

This invention relates to the field of moxibustion stick preparation technology, and discloses a ginseng moxibustion stick with anti-fatigue effect and its preparation method. The preparation method is as follows: Moxa wool is passed through an 80-mesh sieve to remove coarse particles. Then, it is mixed with ginseng extract, schisandrin B, modified chitosan, modified silk fibroin, and glycerin in a three-dimensional mixer for 30-40 minutes. Finally, musk is added, and stirring is continued for 15-20 minutes. After standing and aging for 1-2 hours, an automatic molding machine is used to press the moxibustion stick into a diameter of 1.8 cm and a length of 20 cm using a pressure of 80-100 MPa for 5-10 seconds. The density is controlled to be 0.8-1.0 g / cm³. 3 The ginseng moxa sticks are dried in hot air at 35-45℃ for 4-5 hours, then equilibrated in an environment with 50% humidity for 45-50 hours, and finally vacuum dried to obtain ginseng moxa sticks with anti-fatigue effects. These moxa sticks possess anti-fatigue properties and good antibacterial activity.

The invention provides application of schisandrin B in preparation of a medicine for preventing and / or treating diabetic nephropathy, and belongs to the technical field of biological medicine. The metabolite is applied to screening of drugs for preventing and treating diabetic nephropathy, and the research finds that pyrimidine metabolic disorder exists in the body of a patient with diabetic nephropathy; schisandrin B and pyrimidine metabolism key enzyme have good combining capacity, and the activity level of HK-2 cells in the diabetic nephropathy state simulated by high glucose can be effectively improved. Research finds that compared with HK-2 cells which are not treated by any medicine and are in a high glucose simulated diabetic nephropathy state, after the HK-2 cells are treated by 5 mu M schisandrin B for 48 hours, the cell morphology, activity and quantity are remarkably improved.

The present application relates to the technical field of drug detection, in particular to a method for determining the content of six components in Shengmai Yin soft capsules based on one measurement multiple evaluation. The method uses schisandrol A as an internal standard for one measurement multiple evaluation, establishes the relative correction factors of schisandrol B, angeloylgomisin H, schisantherin A, schisantherin B and schisantherin C, and calculates the content of the above components in Shengmai Yin soft capsules (Dangshen Fang) through the relative correction factors. The specific steps include: preparation of test sample solution; preparation of reference sample solution; chromatographic conditions and system suitability test; determination and calculation. The present application overcomes the single and one-sidedness of the quality control of Shengmai Yin soft capsules (Dangshen Fang), and has important significance for further improving the drug quality control standard and ensuring the clinical efficacy of drugs.

This invention discloses the pharmaceutical use of schisandrin B in the preparation of analgesic drugs, wherein the analgesia is for the treatment or prevention of chemotherapy-induced neuropathic pain, and the analgesic drug can reduce mechanical and cold hyperalgesia in a chemotherapy-induced neuropathic pain model. Pharmacodynamic studies of this invention demonstrate that oral administration of schisandrin B can reduce chemotherapy-induced neuropathic pain, thereby effectively exerting an analgesic effect, and can be used as a therapeutic or preventative analgesic drug.

The invention provides a composition for dispelling effects of alcohol and protecting liver and a preparation method thereof. The alcoholism-relieving and liver-protecting composition comprises a quick-release core pill and a curcumin microsphere coating layer, wherein the quick-release core pill comprises a schisandrin B-phospholipid complex, atractylodes macrocephala polysaccharide, dipotassium glycyrrhizinate and auxiliary materials. In the alcoholism-relieving and liver-protecting composition provided by the invention, the curcumin microspheres directly repair damaged intestinal barriers and reduce endotoxin entering blood from the source, the atractylodes macrocephala polysaccharide improves the steady state of intestinal flora, so that the intestinal health can be consolidated, and the schisandrin B and the dipotassium glycyrrhizinate synergistically and powerfully remove dry free radicals, so that the alcoholism-relieving and liver-protecting composition has the effects of relieving alcoholism and protecting liver. Through the synergistic effect between the intestinal tract and the liver, the bioavailability and the action mechanism of the composition for dispelling effects of alcohol and protecting liver are improved.

This invention discloses the application of Schisandra chinensis in the prevention and treatment of cardiovascular diseases caused by microplastics. The schisandrin B described in this invention is consistent with the "low-dose, long-term" exposure characteristics of microplastics, emphasizing prevention and early intervention, which helps to control the development of cumulative damage. By targeting and inhibiting the sustained activation of aryl hydrocarbon receptors (AhR), it intervenes in the initiation of microplastic-specific toxic pathways at the molecular level, which is expected to more effectively block the chronic damage process and is more fundamental and targeted than general antioxidant / anti-inflammatory strategies that only target downstream symptoms.

This invention belongs to the field of biomedical technology and discloses a Schisandra chinensis exosome-like vesicle-mediated targeted delivery formulation of anisodamine and its application in preventing and treating alcohol-induced liver injury. This invention provides a drug delivery system that improves the water solubility and dispersibility of drugs (such as anisodamine) through carrier-free self-assembled nanoparticle formulations. Simultaneously, it utilizes plant-derived vesicles (such as Schisandra chinensis) for encapsulation, leveraging the excellent biocompatibility, targeting, and penetration of exosome-like vesicles to enhance drug accumulation and bioavailability in liver tissue. This drug delivery system not only promises to solve key challenges in the clinical application of drugs such as poor water solubility and low bioavailability, but also provides a new technical approach for the efficient delivery of natural active ingredients, holding significant theoretical and practical importance for promoting the development of hangover relief health products and liver injury treatment drugs.

This invention provides an LC-MS / MS method for the simultaneous detection of multiple major components of Shengmai Yin (Codonopsis pilosula formula) in plasma. The analytes include syringin, schisandrol A, gomisin D, schisandrol B, gomisin G, schisandrin A, schisandrin A, schisandrin B, codonopsis glycoside I, codonopsis alkynyl glycoside, methyl ophiopogon flavanone A, and methyl ophiopogon flavanone B. The method includes the following steps: preparation of a series of standard curve working solutions; preparation of standard curve samples; preparation of quality control working solutions; preparation of quality control samples; preparation of a mixed internal standard working solution; pretreatment of the standard curve, quality control, and analyte plasma samples using protein precipitation; sample detection; and quantitative determination based on the peak area ratio of the analyte to the internal standard to obtain the standard curve. The methodological investigation results of this invention show that the established method meets the requirements for in vivo biological sample determination, the pretreatment process is simple, and the method has good sensitivity, strong specificity, and high specificity, making it suitable for the detection of compounds with low concentrations.

The present application relates to a crystal form of schisantherin B, a preparation method thereof, a pharmaceutical composition containing the crystal form, and the use of the crystal form in the preparation of a drug for preventing and / or treating diseases. The crystal form of schisantherin B provided by the present application has almost no hygroscopicity, higher solubility, good physical and chemical stability, and bioavailability, ensures the consistent and controllable quality of the raw drug and preparation, reduces the change of drug quality caused by the change of crystal form or impurities, and is beneficial to the storage of the drug.

This invention relates to the use of schisandrin B in the treatment of osteosarcoma. The invention reveals that schisandrin B has a remarkable effect in treating osteosarcoma, inhibiting the growth, proliferation, migration, and invasion of osteosarcoma cells, and inducing osteosarcoma cell apoptosis; it also exhibits a synergistic effect when used in combination with drugs such as cisplatin, improving therapeutic efficacy and reducing toxic side effects.